Loading patent…
AssigneeGenstruct, Inc.
InventorJack Pollard
Estimating the term…
In one aspect, the invention comprises a method of developing an immunosuppressant drug with reduced propensity to induce type II diabetes mellitus symptoms by assaying candidate molecular entities for binding preferentially to leukocyte isoform calcineurin and less preferentially to muscle cell isoform calcineurin. In another aspect, the invention comprises a method for determining the onset, severity, or response to treatment of post-transplant diabetes mellitus comprising determining from a patient at risk of contracting post-transplant diabetes mellitus, at least two of increased expression of HDAC5 protein; increased expression of HNF4A protein; decreased expression of NRF1 protein; decreased expression of PPARGC1 protein; and decreased expression of PPP3CA protein.
A method of developing an immunosuppressant drug with reduced propensity to induce type II diabetes symptoms, the method comprising:
A method for determining the onset, severity, progression or response to treatment of post-transplant diabetes mellitus comprising determining from a patient at risk of contracting post-transplant diabetes mellitus, at least two of:
Dependencies are inferred from the claim text.